Affiliation:
1. Memorial Hospital Of Sun Yat- sen University
2. Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Center for Precision Medicine of Sun Yat-sen University
3. Chengdu University of TCM
4. Sun Yat-sen University
Abstract
Abstract
(1) Background: For N+ breast cancer patients treated with neoadjuvant therapy, the response to the treatment, especially the probability of axillary pathological complete response (apCR), can guide the choice of subsequent surgical strategy.
(2) Method: 50 N+ breast cancer patients were treated with neoadjuvant therapy, with the response to neoadjuvant therapy guiding subsequent surgical modalities. Logistic regression was used to calculate the coefficients of the significant predictors for axillary pathologic complete response (apCR), and a nomogram was developed based on the logistic model and internally validated.
(3) Results: 4 variables were found to be related to the probability of apCR: pathological grade and molecular subtype (HER2+), neutrophil-to-lymphocyte ratio (NLR), and monocyte-to-lymphocyte ratio (MLR). The nomogram based predictive cooperating pathological features and hematological test results can be used to predict apCR in N+ breast cancer patients who had received neoadjuvant chemotherapy(NAC). The receiver operating characteristic (ROC) curve for the nomogram model is 0.929 [95% confidence interval (CI): 0.859–0.998], indicating a good discrimination.
(4) Conclusion: A comprehensive predictive model using clinical data is a useful tool to predict the probability of apCR in N+ breast cancer patients receiving NAC.
Publisher
Research Square Platform LLC
Reference62 articles.
1. American Cancer Society Key statistics for breast cancer. https://www.cancer.org/cancer/breast-cancer/about/how-common-is-breast-cancer.html (4 November 2022).
2. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung H;CA: Cancer J Clin,2021
3. Randomized trial comparing neo-adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer (T4b N0-2 M0);Deo SVS;J Surg Oncol,2003
4. Randomized trial comparing neo-adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer (T4b N0-2 M0);Deo SVS;J Surg Oncol,2003
5. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial;Boughey J,2013